INT179885

Context Info Confidence 0.26 First Reported 2004 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 8 Total Number 10 Disease Relevance 11.88 Pain Relevance 2.18

lipid binding (PTEN) cell proliferation (PTEN) cytosol (PTEN) plasma membrane (PTEN) nucleus (PTEN) enzyme binding (PTEN)

Anatomy Link Frequency nail 1 PTEN (Homo sapiens)

Pain Link Frequency Relevance Heat rheumatoid arthritis 162 99.68 Arthritis 102 99.60 spinal inflammation 93 98.16 Inflammation 64 98.08 alcohol 4 86.20 agonist 9 83.96 psoriasis 15 83.76 spondylitis 3 82.52 Pain score 3 79.20 cytokine 4 62.96

Disease Link Frequency Relevance Heat Endometrial Cancer 612 100.00 Hyperplasia 74 99.96 Rheumatoid Arthritis 165 99.68 Seronegative Spondarthritis 93 99.60 Nail Diseases 6 99.44 Microsatellite Instability 188 98.52 Cancer 416 98.44 Low Back Pain 99 98.16 INFLAMMATION 56 98.08 Disease 91 97.56

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

and/or modulation of the PTEN/PDK1/ILK1/Akt pathway [120].

Regulation (modulation) of PTEN

1) Confidence 0.26 Published 2008 Journal PPAR Research Section Body Doc Link PMC2435221 Disease Relevance 0.38 Pain Relevance 0.04

They are associated with a number of well-described genetic alterations including mutations of PTEN, KRAS, ?

Regulation (alterations) of PTEN

2) Confidence 0.26 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2846683 Disease Relevance 1.29 Pain Relevance 0

In atypical hyperplasia, alterations of PTEN, ?

Regulation (alterations) of PTEN associated with hyperplasia

3) Confidence 0.26 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2846683 Disease Relevance 1.70 Pain Relevance 0

This suggests that PTEN could be a target for mutations in the context of DNA repair deficiency [13].

Regulation (target) of PTEN

4) Confidence 0.26 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2846683 Disease Relevance 1.45 Pain Relevance 0

Furthermore, none of the five main alterations of endometrioid endometrial carcinoma (mutations of PTEN, PIK3CA, KRAS, and CTNNB1 genes and MSI) plays a major role in non-endometrioid endometrial carcinoma.

Regulation (alterations) of PTEN associated with microsatellite instability and endometrial cancer

5) Confidence 0.26 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2846683 Disease Relevance 1.55 Pain Relevance 0

PTEN, an inactivator of the Akt/PKB pathway was down-regulated over 200-fold.

Regulation (regulated) of PTEN

6) Confidence 0.18 Published 2004 Journal Comp Hepatol Section Body Doc Link PMC535891 Disease Relevance 0.37 Pain Relevance 0.03

We found that patient classification models built on the expression values of TGFB1 and PTEN could correctly classify 72% of these samples using a linear support vector machine classifier (SVM) and leave-one-out cross-validation (LOO).

Regulation (values) of PTEN

7) Confidence 0.14 Published 2010 Journal BMC Syst Biol Section Body Doc Link PMC2890499 Disease Relevance 0.13 Pain Relevance 0

The effects of GLM therapy on markers of comorbidities of chronic inflammatory disease have been assessed prospectively in the phase III trials of GLM in RA, PsA, and AS (Tables 2, 3, and 4).

Regulation (effects) of GLM associated with spinal inflammation, inflammation, rheumatoid arthritis, disease and arthritis

8) Confidence 0.06 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 2.75 Pain Relevance 0.90

Additional endpoints in the GLM PsA trial assessed the effects of GLM treatment on nail disease, dactylitis, and enthesitis, which are features of PsA that significantly affect patients but are not typically measured in clinical trials of drug therapies for PsA.

Regulation (effects) of GLM in nail associated with nail diseases and arthritis

9) Confidence 0.06 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 0.83 Pain Relevance 0.39

The GO-RAISE trial was designed to evaluate the efficacy of GLM in treating the signs and symptoms of active AS.

Regulation (efficacy) of GLM associated with spinal inflammation

10) Confidence 0.04 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 1.44 Pain Relevance 0.81

General Comments

This test has worked.